Hospital
Morris Hospital
Morris Hospital was paid $736K by Medicaid between Jan 2018 and Jun 2020, across 75 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 60% of everything it billed.
33Billing provider infoMORRIS HOSPITAL
MORRIS, IL 60450
MORRIS, IL 60450
33aNPI1295882793assigned 01/05/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$736K
24GClaims41,752
24DCodes billed75
24AFirst – last monthJan 2018 – Jun 2020
Compared with peers
Next to other General Acute Care Hospital providers in Illinois
Rank by total paid#55 of 129
Median peer was paid$547K
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,302 | $230K | |
| 2019 | 19,773 | $332K | |
| 2020 | 10,677 | $174K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 60% | 4,526 | 922 | $443K |
| 97161 | 7.1% | 488 | 407 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.8% | 609 | 548 | $35K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.5% | 1,016 | 968 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.0% | 3,044 | 2,945 | $22K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.4% | 297 | 278 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 419 | 395 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 242 | 217 | $12K |
| 80053 | Comprehensive metabolic panel | 1.6% | 4,085 | 3,886 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 688 | 655 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 686 | 653 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,449 | 1,270 | $6K |
63 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,803 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 687 | $6K |
| 86703 | <1% | 736 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 149 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 117 | $3K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 154 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 420 | $3K |
| 87653 | <1% | 84 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 965 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $2K |
| 87186 | <1% | 395 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 930 | $2K |
| 83655 | <1% | 230 | $2K | |
| 80061 | Lipid panel | <1% | 2,057 | $2K |
| 86780 | <1% | 525 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 238 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 477 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,099 | $1K |
| 86803 | <1% | 426 | $1K | |
| 87340 | <1% | 429 | $1K | |
| 80074 | <1% | 56 | $1K | |
| 84439 | <1% | 967 | $1K | |
| 81001 | <1% | 1,546 | $967.47 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 69 | $924.49 |
| 87077 | <1% | 314 | $808.34 | |
| 86769 | <1% | 21 | $783.38 | |
| 82607 | <1% | 275 | $735.84 | |
| 85610 | <1% | 489 | $728.70 | |
| 82950 | <1% | 311 | $712.19 | |
| 87070 | <1% | 250 | $711.79 | |
| 73630 | <1% | 67 | $658.98 | |
| 86850 | <1% | 411 | $467.10 | |
| 86003 | <1% | 13 | $456.51 | |
| 73610 | <1% | 32 | $446.73 | |
| 86901 | <1% | 386 | $398.38 | |
| 86762 | <1% | 296 | $367.30 | |
| 86140 | <1% | 570 | $349.01 | |
| 85652 | <1% | 629 | $227.12 | |
| 83520 | <1% | 15 | $209.78 | |
| 86900 | <1% | 407 | $207.99 | |
| 85730 | <1% | 128 | $207.18 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $195.90 |
| 73564 | <1% | 19 | $194.41 | |
| 84481 | <1% | 134 | $149.29 | |
| 82570 | <1% | 241 | $141.04 | |
| 82746 | <1% | 114 | $139.48 | |
| 83516 | <1% | 30 | $136.70 | |
| 81003 | <1% | 277 | $128.52 | |
| 83540 | <1% | 180 | $102.36 | |
| 86038 | <1% | 42 | $92.70 | |
| 82728 | <1% | 171 | $80.10 | |
| 82043 | <1% | 177 | $67.47 | |
| 84702 | <1% | 22 | $64.69 | |
| 85027 | <1% | 50 | $64.23 | |
| 86431 | <1% | 42 | $59.88 | |
| 83550 | <1% | 45 | $58.25 | |
| 86308 | <1% | 14 | $23.36 | |
| 84550 | <1% | 38 | $21.50 | |
| 85007 | <1% | 17 | $8.51 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 76 | $3.99 |
| 82785 | <1% | 13 | $3.48 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 280 | $0.00 |
| 99283 | Emergency room visit (moderate) | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEADHAM, MARK (CEO)